FDA Approves New Drug for Advanced Prostate Cancer

The FDA has approved Xtandi, a drug designed to treat prostate cancer that has returned or spread despite major medical intervention. According to the National Cancer Institute, more than 241,000 men will be diagnosed with prostate cancer this year and 28,170 will die from the disease.

Xtandi is indicated for patients who have already received the chemotherapy drug docetaxel and testosterone-limiting interventions, such as drugs or surgery.

During a study, patients who took Xtandi survived an average of 18.4 months longer than those who received a placebo treatment.

To learn more, click here.